Steven Gannon

CIK: 0001643085

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (20.0%)

Position reduction

Option Exercises (M)3 (30.0%)

Derivative conversions

Awards (A)4 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (10.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

XENE

Xenon Pharmaceuticals Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (10 total)

XENE
Xenon Pharmaceuticals Inc.
Aug 11, 2026
Sale(S)
Direct
10K shares at avg. $64.06$641K
XENE
Xenon Pharmaceuticals Inc.
Jun 3, 2026
Award(A)
Restricted Share Units
Direct
1.6K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 3, 2026
Award(A)
Share Option (Right to Buy)
Direct
10.5K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 1, 2026
Exercise(M)
Direct
2.6K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 1, 2026
Tax Payment(F)
Direct
1.4K shares at avg. $53.41$76K
XENE
Xenon Pharmaceuticals Inc.
May 12, 2026
Exercise(M)
Direct
3.5K shares at avg. $7.38$26K
XENE
Xenon Pharmaceuticals Inc.
Jun 5, 2025
Award(A)
Share Option (Right to Buy)
Direct
17K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 5, 2025
Award(A)
Restricted Share Units
Direct
2.6K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 5, 2025
Sale(S)
Direct
3 shares at avg. $30.48$91.44
XENE
Xenon Pharmaceuticals Inc.
May 14, 2025
Exercise(M)
Direct
5.1K shares at avg. $12.57$65K

		Type	Shares	Price		Ownership
Aug 11, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	10,000	$64.06	$640,550	Direct
Jun 3, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	1,593	-	-	Direct
Jun 3, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	10,507	-	-	Direct
Jun 1, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	2,645	-	$0	Direct
Jun 1, 2026	XENE Xenon Pharmaceuticals Inc.	Tax Payment(F)	1,416	$53.41	$75,629	Direct
May 12, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	3,500	$7.38	$25,830	Direct
Jun 5, 2025	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	17,012	-	-	Direct
Jun 5, 2025	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	2,645	-	-	Direct
Jun 5, 2025	XENE Xenon Pharmaceuticals Inc.	Sale(S)	3	$30.48	$91	Direct
May 14, 2025	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	5,144	$12.57	$64,660	Direct

1-10 of 10 transactions

About GANNON STEVEN

GANNON STEVEN (SEC CIK 0001643085) files insider reports with the SEC as Director of Xenon Pharmaceuticals Inc. (XENE).

Signal8 holds 5 ownership filings by GANNON STEVEN, all Form 4s, filed between May 16, 2025 and Aug 13, 2026. Those filings report 10 transactions, from May 14, 2025 to Aug 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on GANNON STEVEN's filings is in BURNABY.

Recent filings by GANNON STEVEN

Aug 11, 2026: Open-market sale of XENE shares (Form 4, code S).
Jun 3, 2026: Grants or awards of XENE derivative securities (2 lines, Form 4, code A).
Jun 1, 2026: Option exercise of XENE shares (Form 4, code M).
Jun 1, 2026: Tax withholding of XENE shares (Form 4, code F).
May 12, 2026: Option exercise of XENE shares (Form 4, code M).

Other insiders filing for Xenon Pharmaceuticals Inc. (XENE)

Kelly Thomas Patrick, Chief Financial Officer
MORTIMER IAN, PRESIDENT & CEO
Svoronos Dawn, Director
PATOU GARY, Director
Cannon Gillian, Director
Machado Patrick, Director

How to read Form 4 transaction codes